Literature DB >> 33916034

Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution.

Laura Bergantini1, Miriana d'Alessandro1, Elda De Vita1, Felice Perillo1, Antonella Fossi1, Luca Luzzi2, Piero Paladini2, Anna Perrone1, Paola Rottoli1, Piersante Sestini1, Elena Bargagli1, David Bennett1.   

Abstract

BACKGROUND: The immune mechanisms occurring during acute rejection (AR) and chronic lung allograft dysfunction are a challenge for research and the balance between effector and regulatory cells has not been defined completely. In this study, we aimed to elucidate the interaction of effector cells, mainly Th17, Th1 and Th2, and regulatory cells including (CD4+CD25+CD127low/-) T reg cells and phenotypes of B regs, CD19+CD24hiCD38hi, CD19+CD24hiCD27hi and CD19+CD5+CD1d+.
METHODS: Bronchoalveolar lavage cells (BAL) and peripheral blood mononuclear cells (PBMCs) from stable lung transplanted (LTx )subjects (n = 4), AR patients (n = 6) and bronchiolitis obliterans syndrome (BOS) (n = 6) were collected at the same time. Cellular subsets were detected through flow cytometry.
RESULTS: A predominance of Th17 cells subtypes in the PBMCs and BAL and a depletion of Tregs, that resulted in decrease Treg/Th17 ratio, was observed in the AR group. CD19+CD24hiCD38hi Bregs resulted increased in BAL of AR patients. Th1 cells predominance and a reduction of Tregs cells was observed in BAL from AR patients. Moreover, multivariate analysis showed interdependences within studied variables revealing that effector cells and regulatory cells can effectively discriminate patients' immunological status.
CONCLUSIONS: In AR, BOS and stable lung transplant, regulatory and effector cells clearly demonstrated different pathways of activation. Understanding of the balance of T cells and T and B regulatory cells can offers insights into rejection.

Entities:  

Keywords:  acute rejection; bronchiolitis obliterans syndrome; chronic lung allograft dysfunction; effector T cells; flow cytometry; lung transplantation; regulatory cells

Year:  2021        PMID: 33916034     DOI: 10.3390/cells10040780

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  5 in total

1.  Mechanisms of Action of Extracorporeal Photopheresis in the Control of Bronchiolitis Obliterans Syndrome (BOS): Involvement of Circulating miRNAs.

Authors:  Sara Bozzini; Claudia Del Fante; Monica Morosini; Hatice Oya Berezhinskiy; Sophia Auner; Elena Cattaneo; Matteo Della Zoppa; Laura Pandolfi; Rosalia Cacciatore; Cesare Perotti; Konrad Hoetzenecker; Peter Jaksch; Alberto Benazzo; Federica Meloni
Journal:  Cells       Date:  2022-03-25       Impact factor: 6.600

2.  NK and T Cell Immunological Signatures in Hospitalized Patients with COVID-19.

Authors:  Laura Bergantini; Miriana d'Alessandro; Paolo Cameli; Dalila Cavallaro; Sara Gangi; Behar Cekorja; Piersante Sestini; Elena Bargagli
Journal:  Cells       Date:  2021-11-15       Impact factor: 6.600

3.  Characterization of NKG2-A/-C, Kir and CD57 on NK Cells Stimulated with pp65 and IE-1 Antigens in Patients Awaiting Lung Transplant.

Authors:  Laura Bergantini; Miriana d'Alessandro; Ambra Otranto; Dalila Cavallaro; Sara Gangi; Antonella Fossi; Felice Perillo; Luca Luzzi; Edoardo Zanfrini; Piero Paladini; Piersante Sestini; Paola Rottoli; Elena Bargagli; David Bennett
Journal:  Life (Basel)       Date:  2022-07-19

4.  The Role of Galectins in Chronic Lung Allograft Dysfunction.

Authors:  Miriana d'Alessandro; Laura Bergantini; Antonella Fossi; Elda De Vita; Felice Perillo; Luca Luzzi; Piero Paladini; Piersante Sestini; Paola Rottoli; Elena Bargagli; David Bennett
Journal:  Lung       Date:  2021-05-03       Impact factor: 2.584

5.  Interleukin-18: A Novel Participant in the Occurrence, Development, and Drug Therapy of Obliterative Bronchiolitis Postlung Transplantation.

Authors:  Ping Shu; Wei Zhang; Yanfei Zhang; Yanfeng Zhao; Yuping Li; Xiaoqing Zhang
Journal:  Dis Markers       Date:  2021-07-27       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.